Aug 4, 2004 by Charly TraversLabs' Report Offers Mixed ResultsThe company's royalty intake looks great, but its drug development does not.
Aug 3, 2004 by Charly TraversBlack Cloud Over LigandThe pharmaceuticals company misses estimates and loses an auditor. What's up?
Aug 2, 2004 by Charly TraversWhat's a Drug Worth?The value of small biotech companies is in their investigational drug programs.
Jul 27, 2004 by Charly TraversCash Concerns at VertexNew royalties might not help offset losses, so it's time to look at the drug pipeline.
Jul 22, 2004 by Charly TraversPatience With MedImmuneDrug development is a lengthy process. Is it worth the wait?
Jul 22, 2004 by Charly TraversA Millennium Pharmaceuticals MixSales for one drug are encouraging, while sales for another one are declining.
Jul 13, 2004 by Charly TraversWith Pfizer Drug, HIV RetreatsPfizer's newest HIV treatment shows promise in a demanding market.
Jul 9, 2004 by Charly TraversProtein Design Labs' WindfallRoyalties from Genentech could mean big things for PDL.
Jul 8, 2004 by Charly TraversGenentech's Next Billion-Dollar DrugThe cancer drug Avastin looks like a big winner.
Jul 7, 2004 by Charly TraversPfizer Wants to Be Your PfriendA new drug program for uninsured and low-income Americans goes the extra mile.
Jun 29, 2004 by Charly TraversAntegren Gets Priority ReviewThe FDA steps up the drug's time line for approval.
Jun 23, 2004 by Charly TraversSEC Goes After Drug FraudA private firm is under investigation for misleading information and securities fraud.
Jun 22, 2004 by Charly TraversMerck Pays Up for a Cancer DrugThe big pharma company makes a deal with Vertex.
Jun 21, 2004 by Charly TraversBiotech's Full MonteThe Monte Carlo method is an alternate way to model drug sales estimates.
Jun 17, 2004 by Charly TraversNo Heartburn for SantarusThe small drug company is taking on big pharma.
Jun 15, 2004 by Charly TraversQLT Swallows AtrixTwo small drug companies get together to do bigger things.
Jun 7, 2004 by Charly TraversUnraveling Biotech PotentialCharly Travers shows investors how to forecast the potential of drug sales.
Jun 3, 2004 by Charly TraversNew Chapter for IndevusThe drug company puts troubled history behind it with the launch of Sanctura.
Jun 3, 2004 by Charly TraversSmall Drug Market, Big HopesBioMarin's Aryplase was successful in a phase 3 trial.
